SM

Sanjay Mistry

Vice President Venture Investments New Company Creation - Johnson & Johnson Innovation – JJDC Inc.

San Diego, California

Invests in

Stages:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Director Board of Directors

    2024

  • Board Observer

    2021

  • Vice President Venture Investments New Company Creation - Johnson & Johnson Innovation – JJDC Inc.

    2021

    Senior investment professional leading new company creation for Johnson & Johnson Innovation – JJDC, Inc., the strategic venture capital arm of the Johnson & Johnson Family of Companies. Primary responsibility is to fund compelling innovation where we see an opportunity to transform and enhance patient outcomes through the creation of innovative healthcare start-up companies.

  • Head JLABS @ San Diego, Johnson & Johnson Innovation

    2019 - 2021

    Nurtured the growth of San Diego’s entrepreneurial start-ups focusing on accelerating the pace of innovation that is critical for translating discoveries into products for patients

  • Senior Finance Director Business Operations for Janssen Pharmaceuticals R&D

    2018 - 2019

    Reported to Janssen Pharmaceuticals R&D CFO

  • Head of External Value Creation & Business Operations/Venture Leader

    2013 - 2018

    Led Janssen R&D efforts on launching NewCo’s via the out-licensing of R&D pre-clinical/clinical portfolio assets to biotech’s, pharma’s or into venture backed entities Led Janssen R&D Internal Venture Incubator operations focused on disruptive drug discovery assets/platforms that could generate new business models/innovation within or external to Janssen beyond core strategic focus areas EIR for 2 internal ventures

2022 - 2024

  • Director Board of Directors

    2022 - 2024

2008 - 2013

  • Vice President

    2008 - 2013

    Board Observer Roles: Raindance Technologies, Tarsa Therapeutics, Corridor Pharmaceuticals, Rapid Micro Biosystems, Durata Therapeutics (PIPE)

2003 - 2008

  • Assistant Director

    2003 - 2008

    Inventor of cell therapy for the treatment of age-related macular degeneration (Phase iIIb)

  • Development Scientist

    2002 - 2003

    Established stem cell molecular biology group and discovered and developed muscle derived stem cell platform

  • Postdoctoral Fellow

    2000 - 2001

    Investigated the role of neural cell adhesion molecules in the initiation of stem cell differentiation and integration in targeted organogenesis (Laboratory of Dr. G. Edelman, Nobel laureate)

1998 - 2000

  • Postdoctoral Fellow

    1998 - 2000

    Department of Biochemistry: Investigated the role of arginase in arginine metabolism in wound healing and trauma (Laboratory of Dr. S. Morris)